Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MTOR | P42345 | 3/20 | 0.43 |
| ▸ | C5AR1 | P21730 | 3/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | CKS1B | P61024 | 2/20 | 0.41 |
| ▸ | SKP1 | P63208 | 2/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14328064 | 0.78 | P2RX7 (0.49) | MAPTMTORC5AR1PDE10ACKS1B | |
| SCHEMBL2334926 | 0.78 | MTOR (0.42) | MAPTMTORPIK3R1PIK3CA | |
| SCHEMBL2343551 | 0.77 | CYP2C19 (0.43) | MAPT | |
| SCHEMBL184023 | 0.76 | HTR2A (0.51) | MAPTMTORC5AR1PDE10AESR2 | |
| SCHEMBL16610537 | 0.73 | PRLHR (0.41) | MAPTMTORC5AR1PDE10AGPR119 | |
| SCHEMBL24699477 | 0.72 | ALDH1A1 (0.47) | MAPT | |
| SCHEMBL25526820 | 0.71 | MTOR (0.47) | MAPTMTORC5AR1PDE10AESR2 | |
| SCHEMBL12706798 | 0.71 | MAPT (0.59) | MAPTMTORC5AR1PDE10AGPR119 | |
| SCHEMBL193036 | 0.71 | HTR2A (0.52) | MTORC5AR1PDE10ACKS1BSKP1 | |
| SCHEMBL17523460 | 0.70 | MTOR (0.47) | MAPTMTORC5AR1PDE10AESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829011-B2 | 2-aminopyrimidine compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-09 | — | — | US | disclosed |
| US-20110207717-A1 | 2-AMINOPYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207717-A1 | 2-AMINOPYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | HTR2A, HTR6, HTR5A | MAPT 1772/4885MTOR 746/4885C5AR1 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.